| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 7.22 | 18.1% |
| Total Income | 7.22 | 18.1% |
| Expenditure | 71.34 | 25.2% |
| PBT | -61.69 | 39.4% |
| Net Profit | -61.45 | 47.4% |
| OPM | — | |
| NPM | — | |
| EPS | -1.07 | 34.0% |
Generate Biomedicines Reports Q1 2026 Financial Results
07 May 2026 · 7 May, 3:42 pm
Summary
Generate Biomedicines reported its financial results for the first quarter ended March 31, 2026. The company had approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which includes $369.3 million in net proceeds from the IPO. Revenue for the quarter was $7.2 million, compared to $8.8 million for the same period in 2025. Net loss for the quarter was $61.7 million, compared to $44.3 million for the same period in 2025.
Key Highlights
- 1
Generate Biomedicines reported approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
- 2
First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T).
- 3
Revenue for the quarter ended March 31, 2026, was $7.2 million, compared with $8.8 million for the same period in 2025.
- 4
Research and development expenses were $57.8 million for the quarter, compared with $46.8 million for the same period in 2025.
- 5
Net loss was $61.7 million for the quarter ended March 31, 2026, compared with $44.3 million for the same period in 2025.
- 6
Net cash used in operating activities was $80.4 million for the quarter ended March 31, 2026, compared with $53.2 million for the same period in 2025.
Management Comments
Mike Nally
“We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform,” “We are advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD. In oncology, we expect to progress two clinical trials this year with GB-4362, an MMAE neutralizer, and GB-5267, a MUC16 CAR T developed with Roswell Park. Together, these programs reflect the breadth of our clinical portfolio across therapeutic areas, modalities, and both wholly owned and partnered programs.”
Informational and educational content only. Not investment advice.